Proactiveinvestors One2One Forum this Thursday: Lonrho, Fusion IP, Forbidden Technologies and Sphere

After a diet of resources stocks we have decided to change the menu this week.

So we are serving up exciting growth companies from the technology and medical devices sectors and well known name from the past that reflects the changing face of business in Africa today. 

Lonrho (LON:LHRO),  Fusion IP (LON:FIP), Forbidden Technologies’ (LON:FBT) and Sphere Medical (LON:SPHR) are expected to provide investors with plenty of food for thought when they present to Thursday’s One2One Forum.

As those of you who joined us last week will know, the London event is now incredibly popular. So to avoid disappointment, register now by clicking on this link.

Up almost 80 per cent in the past year, shares in Fusion IP has been among the few bright stars of AIM.  

In recent months the group has helped its investee companies raise around £8 million, and chief executive David Baynes says there's more to come. 

Fusion acts as an incubator, supporting the business financially and practically as it develops and advances its IP into a commercial product. 

The company then realises the added value with an ‘exit’ once the investee is well established. 

Among the current crop of companies Diurnal, a developer of hormone therapy drugs, is one of the more advanced. And it may be one of Fusion’s investments nearest to an exit. To learn more, join us on Thursday when Baynes will address our One2One Forum.

It wasn’t just Britain’s Olympians and Parlympians who enjoyed success in London this summer.

Forbidden Technologies emerged as one of the big winners from the games after its video editing platform FORscene was used to process 20,000 hours of some of the most spectacular action of the games.

The 25 per cent rise in Forbidden Technologies’ (LON:FBT) share price in the past six month suggests investors starting to get the potential of the company and its technology. Find out why this is only the start of Forbidden’s journey on Thursday when we are joined by chief executive Stephen Streater.

Sphere Medical’s lead product is a potentially revolutionary device, which analyses blood gases and can be used in hospital operating theatres or intensive care units. 

It’s passed a number of technical milestones this year, which means Sphere is now turning its attention to finding commercial partners for the technology. 

Chief executive Dr Stuart Hendry told Proactive recently: "We are talking to some very significant companies who are all very interested in marketing the product."

The Lonrho name will have a resonance with investors of a certain vintage.

However the story today is about the future of Africa, and particularly the economic and social renaissance of the continent, rather than its past. It has spent three years putting the infrastructure in place to be able to meet the constantly rising demand for food. 

"Africa is going to become increasingly significant as a global producer, not just for the billion people in Africa that are becoming much more affluent, but also as a major exporter to meet the demands from ever growing global food consumption," chief executive Geoffrey White told Proactive Investors recently.

Hear more about White’s vision and Lonrho’s transformation into an integrated agri-logistics business when he presents with us this week.